Introduction
The regulation of platelet production is a highly complex process, governed by multiple cytokines, and by various cellular processes, including cell proliferation, differentiation, maturation, endomitosis, and platelet shedding. While the number of platelets in normal animals and humans is maintained in a relatively narrow range, both decreased and increased platelet production outside this range may lead to pathologic conditions, such as bleeding or thrombosis, respectively. There is a hierarchy of cells in the bone marrow, starting from the pluripotent hematopoietic stem cells, multipotent progenitor cells, progenitors which have been committed to differentiate to the megakaryocytic lineage, and megakaryocytes (MKs), which ultimately produce platelets. 1 Recently, both thrombopoietin (TPO), the primary regulator of this developmental pathway, and its cellular receptor, the product of the protooncogene c-mpl, have been cloned, and characterized. 2 In a number of cell culture systems, TPO has been shown to affect all phases of MK development, including the survival, proliferation, and differentiation of the hematopoietic stem cell all the way down to the mature MK. [3] [4] [5] [6] [7] In keeping with these in vitro findings, the genetic elimination of tpo, or c-mpl in vivo, has been shown to result in a marked reduction in the levels of hematopoietic stem cells, multipotent and committed MK progenitors, mature MKs, and blood platelets, [8] [9] [10] indicating that TPO is the principal humoral regulator controlling MK and platelet production.
Studies of the intracellular signaling pathways utilized by MPL have indicated that, after stimulation with TPO, MPL undergoes a conformational change and forms a homodimeric receptor complex, which then supports transphosphorylation and activation of two tethered Janus kinases, JAK2 and TYK2. [11] [12] [13] [14] The role of JAK2 is still somewhat controversial since one study reported that JAK2, but not TYK2, is necessary for subsequent signaling events, 15 while others have questioned this view. 16 Regardless of such a dispute, Janus kinases, once activated, phosphorylate a number of substrates, including MPL itself which provides a docking site for SH2-containing proteins, the latent transcription factors such as signal transducers and activators of transcription (STAT) 3 and STAT5, and a number of adapter proteins including SHC and SHP2. Other signaling intermediates that also play a vital role in MK development such as mitogen-activated protein kinase (MAPK), 17, 18 protein kinase C, 19, 20 and PI3K, 16, 21, 22 have also been found to be activated by TPO in various cell lines. For example, TPO-induced MAPK activation was shown to be both SHC-dependent and -independent both in cell lines and in platelets. 23, 24 SHC-independent pathway of MAPK activation that follows TPO signaling remains undefined as yet.
Recent studies have shown that PI3K prevents programmed cell death by activation of Akt, leading to phosphorylation and sequestration of Bad, an apoptosis-promoting Bcl family member. 25 It is known that several hematopoietic cytokines, including IL-3, 25, 26 erythropoietin (EPO), 27, 28 and IL-6, 29 can activate PI3K and Akt. However, PI3K mediates several other additional cellular events. 30 For example, PI3K stimulates the Ras/Raf/MEK/MAPK and GSK-3␤/␤-catenin/LEF pathways, both of which play an important role in cellular proliferation. In MPL-Ba/F3 cells, certain proteins such as SHP2, Gab2 and IRS2 undergo autophosphorylation and association following exposure to TPO, then they are involved in the recruitment and enhancement in the enzymatic activity of PI3K. Furthermore, SHP2 has been shown to be important for full PI3K activation suggesting the critical role of Gab/IRS proteins in the recruitment of SHP2 and PI3K into the same complex. 31 Activating mutations have been reported in the transmembrane domain as well as in the extracellular domain, but not in the intracellular domain, of MPL. In addition to MPL, activating mutations have been reported in the erythropoietin receptor (EpoR), 32 a closely related member of the cytokine receptor superfamily to Mpl, and in the common ␤-subunit of the IL-3, granulocyte/macrophage colony-stimulating factor (GM-CSF), and IL-5 receptors. 33 In this study, we have isolated a novel, spontaneously occurring, activating mutation of MPL in Ba/F3 cells which had been transfected with MPL. This mutation caused an amino acid substitution of Trp 508 to Ser 
Materials and methods

Antibodies and cytokines
Cell line and cell culture condition
Ba/F3 cells, a pre-B cell line derived from Balb/c mice, were engineered to express the human MPL 34 and were cultured in RPMI 1640 medium (Gibco BRL) supplemented with 10% fetal calf serum (FCS), 0.5% penicillin/streptomycin mixture (Gibco BRL) and 0.5% WEHI conditioned media (Becton Dickinson, Bedford, MA, USA) as a source of IL-3.
Sequencing of MPL
MPL sequences were recovered from c-mpl-transfected Ba/F3 cells and the factor-independent Ba/F3 clones by RT-PCR using a set of MPL primers, (5′-GGGTCTAGAG-TATGGTCCCCTCCTGGGCCCTCTTCATG-3′ [5′ primer] and 5′-GGGTCAAGGCTGCTGCCAATAGCTTAGT-3′ [3′ primer]). The resulting PCR fragments were purified from agarose gel using QIAquick Gel Extraction Kit (Qiagen, Chatsworth, CA, USA). Then, for confirmation of the detected mutations, each PCR fragment from the bulk products was cloned into the pCR-Blunt II-TOPO vector, and obtained clones were sequenced. Sequencing reaction was performed using Taq DyeDeoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Menlo Park, CA, USA), and then the sequence was analyzed on an Applied Biosystems model 3700 sequencer.
Cell proliferation assay
For cell proliferation assay, 2 × 10 5 cells/ml (Ba/F3 cells or Ba/F3 clones that stably expressed either MPL M or MPL W ) were seeded in each well of a 96-well plate and cultured for 24 h in RPMI 1640 medium supplemented with 10% FCS and 0.5% penicillin/streptomycin, either in the absence or presence of various concentrations of TPO. Cell proliferation was assessed by a spectrophotometric assay of NAD(P)H based on tetrazolium salt formation (Dojin Co. Ltd, Kumamoto, Japan).
Western blotting
Exponentially growing cells, washed free of serum and growth factors, were incubated in RPMI1640 supplemented with Leukemia 0.5% BSA for 15 h at 37°C. After this depletion period, cells were resuspended in RPMI1640 at a concentration of 5 × 10 7 /ml and were stimulated with 10 ng/ml mIL-3 or 500 ng/ml hTPO at 37°C for 10 min. Cells were then lysed in the same volume of a buffer containing 15 mM Hepes (pH 7.4), 150 mM NaCl, 10 mM EGTA, 1 mM sodium orthovanadate, protease inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN, USA), and 2% (w/v) TritonX-100. Insoluble materials were removed by centrifugation at 10 000 g for 15 min at 4°C. For the detection of MPL with anti-MPL antibody, the loading buffer was directly added to cell pellets without the depletion period. Total lysates were separated by electrophoresis using an SDS-PAGE gel under reducing conditions and transferred to a sheet of polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was then blocked with Block Ace (Dainihon-Seiyaku, Osaka, Japan) at room temperature for 30 min. Membranes were then incubated overnight at 4°C in a hybridization buffer consisting of anti-phospho-SHC, anti-phospho-Raf-1, anti-phospho-ERK, anti-phospho-JNK, anti-phospho-JAK2, anti-phospho-STAT3, anti-phospho-STAT5, anti-phospho-Akt, anti-phospho-Bad, and anti-MPL antibodies in Tris-buffered saline with 0.05% Tween 20 (TBST) and 3% FBS. These filters were stripped and reprobed with anti-SHC, anti-Raf-1, anti-ERK, anti-JNK, anti-JAK2, anti-STAT3, anti-STAT5, anti-Akt, and anti-Bad antibodies to ensure equal loading in each lane of the gel. Blots were developed using an ECL kit (Amersham Pharmacia, Buckinghamshire, UK).
Results
Identification of an activating mutation of MPL
To obtain TPO-independent Ba/F3 cells, we transfected c-mpl into Ba/F3 cells by electroporation. Two Ba/F3 clones spontaneously growing in an IL-3-independent manner were isolated by limited dilution using 96-well multititer plates. MPL clones were isolated by RT-PCR using MPL primers. Nucleotide sequence analysis revealed that both clones carried the identical point mutation (G 1523 to C 1523 ) in the sequence encoding the cytoplasmic region of MPL resulting in an amino acid substitution of Trp 508 to Ser 508 ( Figure 1) . In order to confirm that this mutation of MPL was responsible for constitutive activation of MPL, we transfected Ba/F3 cells with the c-mpl with the constructed mutation. Ba/F3 cells expressing the artificially introduced mutant MPL (designated MPL M ) also resulted in IL-3-independent growth, confirming that the MPL M mutation was indeed responsible for constitutive activation of MPL. It should be noted that the MPL M -mediated IL-3-independent growth was specific to Ba/F3 cells, since MPL M did not abrogate the IL-3 dependency of 32D clone3 cells, 35 another murine IL-3-dependent cell line (data not shown). 8) were subjected to Western blot analysis and the specific bands were detected using an MPL antibody (Genzyme). Clones that were tested for proliferation in the presence or absence of hTPO (see Figure 3 ) are as follows: lane 2, W2; lane 3, M1; lane 6, M4. These clones were also subjected to further characterization. conferred to these cells an IL-3-independent growth property ( Figure 3) . It is particularly noteworthy that all clones expressing MPL M can grow even in the complete absence of FCS (data not shown). For example, IL-3-independent M1 and M4 cells proliferated even in the absence of hTPO and FCS, and their growth was not enhanced by the addition of hTPO (Figure 3) . The conditioned media of these cells were analyzed for the presence of mIL-3 or hTPO, but neither of these factors were detected (data not shown), suggesting that cells of M1 and M4 clones grew without requiring these cytokines. than did M1. Comparison of the levels of phosphorylation of these molecules in factor-independent cells showed that it was considerably lower in the factor-unstimulated state than those observed in the factor-stimulated state, indicating that phosphorylation of these molecules can be further enhanced by the addition of mIL-3 or hTPO.
Generation of Ba/F3 cells expressing either the wildor the mutant-type MPL
Signal transduction pathways activated by MPL
Discussion
In this study, we have identified a novel spontaneously occurring point mutation of MPL, resulting in a Trp 508 to Ser 508 substitution in the intracellular domain of the protein, and defined the functional consequences of the mutation. Ba/F3 cells expressing MPL M were found to proliferate without requiring cytokines and serum. All MPL mutants which had artificially constructed amino acid substitutions had mutations either in the transmembrane domain or in the extracellular domain of the protein, and constitutively activated the signal transduction pathway in Ba/F3 cells that can also be activated by the normal MPL. 36, 37 In contrast, the MPL M described in this study is the first spontaneously occurring point mutation with an amino acid substitution in the intracellular domain of the protein, but it is capable of constitutive activation of signal transduction pathways.
The process of how MPL M leads to constitutive activation remains unclear. One possible mechanism is that this mutation may induce receptor homodimerization. Ligandinduced homodimerization or heterodimerization is a prerequisite step for the activation of most cytokine receptors. [32] [33] [34] 36, 38 In the case of MPL, the essential role of homodimerization has
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Figure 5
Constitutive phosphorylation of the SHC/Raf-1/ERK or SHC/JNK pathway in Ba/F3 cells expressing MPL M . Total cell lysates of parental Ba/F3 cells and W2, M1 and M4 cell clones that had been treated with buffer alone (−), 500 ng/ml hTPO, or 10 ng/ml mIL-3 for 15 min at 37°C were blotted and probed with anti-phospho-SHC, antiphospho-Raf-1, anti-phospho-ERK, or anti-phospho-JNK antibodies (anti-P-, upper panel). The filters were then stripped and reprobed with anti-SHC, anti-Raf-1, anti-ERK, or anti-JNK antibodies as indicated in the figure.
Figure 6
Constitutive phosphorylation of the Jak2/STAT3/STAT5 pathway in Ba/F3 cells expressing MPL M . Total cell lysates of parental Ba/F3 cells and W2, M1 and M4 cell clones were prepared as described in the legend for Figure 5 , and were probed with anti-phospho-Jak2, anti-phospho-STAT3, or anti-phospho-STAT5 antibodies (anti-P-, upper panel). The same filter was then stripped and reprobed with antibodies as indicated (lower panel). been demonstrated by the substitution of cysteines, which are involved in a disulfide bond formation at the dimer interface homology domain, or by using an agonistic bivalent antibody which binds with MPL, or by dimerization of MPL at the plasma membrane or in the cytoplasm with the use of a dimerizer. 34, 36, 39 Constitutive activation of EpoR and the common ␤ subunit of the IL-3, GM-CSF, and IL-5 receptors are also known to result from a mutation that leads to constitutive dimerization of these proteins. 32, 33 EPO binding to EpoRs has been unequivocally demonstrated and defined in detail by crystallization analysis. 38 In contrast, TPO binding to MPLs has not yet been demonstrated. Thus it appears to be very useful if a constitutive dimerization mutant such as MPL M can be crystallized.
To gain insight into the mechanism by which MPL M converts cells from a factor-dependent to a factor-independent growth state, several intracellular signaling events were examined. Our results demonstrated that three major signal transduction pathways, the SHC-Ras-Raf-ERK/JNK cascade, the JAK-STAT pathway, and the PI3K-Akt-Bad pathway, were all activated in factor-independent cells without stimulation by IL-3 or TPO, although levels of SHC, Raf-1, ERK, JNK, JAK2, STAT3, STAT5, Akt, and Bad tyrosine phosphorylation in unstimulated cells were only a small fraction of those that were observed in TPO-stimulated cells ( Figures 5, 6 and 7) . These data suggest that a small degree of activation by MPL M observed in factor-independent cells is sufficient for continued cellular proliferation. Tyrosine phosphorylation was observed within 15 min, while cellular proliferation was observed at 24 h, suggesting that initial tyrosine phosphorylation may permit cells to undergo continued growth. Further work is necessary to clarify the mechanism(s) by which MPL M stimulates cellular growth, but the use of a mutational approach, as shown in this study, should be useful for gaining new insight into this process.
It has been reported that a 10 amino acid in the intracellular domain proximal to the transmembrane region is necessary for the JAK/STAT signaling pathway 40 that includes Trp 508 in MPL. It also appears that Ser residues in the intracellular domain may play an important role in TPO-induced signaling, since an amino acid substitution of Ser 524 to Ala 524 resulted in a nearly complete abrogation of TPO-induced cellular proliferation as well as co-precipitation of JAK2 with MPL. 41 It has been recently reported that, in the human GM-CSF receptor ␤ subunit, Ser 538 binds to the intracellular signaling molecule 14-3-3 in vivo and in vitro.
42 Since 14-3-3 is known to bind to c-Raf and lead to MAPK activation, it is possible that the Ser 508 residue in MPL may also bind to 14-3-3, thereby contributing to cellular proliferation and survival.
It has been suggested that constitutive activation of JAKs may be associated with transformation in various cellular systems. 37, 43, 44 Using the sequence near the transmembrane portion of MPL, Kitamura et al 45 examined whether there might be a mutant in 43 patients with various hematological disorders, including essential thrombocytosis (ET), AML-M7 (megakaryoblastic leukemia), and myelodysplastic syndromes (MDS). While all these patients were found to have two base insertions in intron 10, which resulted in a truncated MPL, no Trp 508 mutation was found in any of these patients. These findings suggest that the Trp 508 MPL mutation, which is present in exon 9, is not a hot spot mutation in leukemogenesis. The close association of a truncated MPL due to the two base substitutions in intron 10 with the hematological disorders is of considerable interest, but its cause-effect relationship remains unclear. It is possible that Trp 508 mutation of the MPL might be found in some other hematological disorders if more patients were to be studied.
In this study, we reported a novel spontaneously occurring mutation of MPL, with an amino acid substitution of Trp 508 to Ser 508 in the intracellular domain that elicits a factor-independent growth of Ba/F3 cells. We examined cellular proliferation, rather than cellular differentiation. It is possible that MPL M -transfected progenitor cells might have proliferated without undergoing terminal cellular differentiation. If this is the case, it may be useful to evaluate the potential of such cells for use in gene therapy. Our future studies will focus on the events leading to cellular differentiation, and evaluate whether MPL M -transfected hematopoietic progenitor cells may be amenable for use in gene therapeutic trials.
